What Is HemoHIM? An Honest Guide to Atomy’s Herbal Supplement

Short answer: HemoHIM is a liquid herbal supplement from South Korea, sold in 20 ml sachets. It is an extract of three plant roots — Angelica gigas, Cnidium officinale and peony (Paeonia lactiflora) — with honey and corn syrup. It was developed by the Korea Atomic Energy Research Institute (KAERI) together with the manufacturer Kolmar BNH and is sold by Atomy. In South Korea it is a registered health functional food with two approved claims: it “may help improve immune function” and “may help reduce fatigue”. It is not a medicine, and the human evidence behind it is limited. The label also lists other ingredients, such as fructo-oligosaccharide, guar gum and small amounts of vitamins; check the label for your country.

This guide explains what is known and what is not. Please note: this site is run by an independent Atomy distributor, not by Atomy or the manufacturer.

Who makes and sells HemoHIM

• Research: KAERI, a South Korean national research institute, developed the herbal formula and studied it in laboratory, animal and small human studies.

• Manufacturing: Kolmar BNH, a Korean health-food manufacturer, makes the product.

• Sales: Atomy, a South Korean direct-selling (multi-level marketing) company founded in 2009, sells it through its own online mall and members in many countries.

Because Atomy sells through registered members rather than shops, you will not normally find genuine HemoHIM in pharmacies or health food stores.

The ingredients in HemoHIM

HemoHIM is a standardized extract of three roots used in traditional Korean herbal medicine. The US label lists 20 kcal, 5 g of carbohydrates and 2.5 g of sugars per sachet, which comes mainly from the honey and corn syrup.

Angelica gigas (Korean angelica)

A plant of the carrot family (Apiaceae), long used in Korean herbal medicine. Its root contains coumarins such as decursin, which have been studied mainly in the laboratory.

Cnidium officinale

Also an Apiaceae plant, traditionally used in Korean medicine. It contains compounds such as ferulic acid and ligustilide. Its traditional uses have not been tested in people taking HemoHIM.

Peony root (Paeonia lactiflora)

A member of the peony family (Paeoniaceae). Its root contains paeoniflorin and related compounds, which have been studied in laboratory and animal research.

For more on each herb and the extract, see our guide to HemoHIM ingredients.

Regulatory status: Korea and elsewhere

• South Korea: the Ministry of Food and Drug Safety (MFDS) registers HemoHIM as a health functional food. Its approved claims are that it “may help improve immune function” and “may help reduce fatigue”, with an intake of one sachet twice a day.

• United States: the FDA does not approve dietary supplements, so HemoHIM is not “FDA approved” — no supplement is. Kolmar BNH announced in October 2024 that its Sejong plant received an FDA “No Action Indicated” (NAI) classification after a September 2024 inspection. That is a statement about the factory, not an approval of the product.

• Australia: Kolmar BNH states that the same plant received a GMP certificate from the Therapeutic Goods Administration (TGA) in 2021. Again, this concerns manufacturing, not the product’s effects.

In other countries HemoHIM is usually sold as a food supplement under local rules, which differ from country to country.

HemoHIM benefits: what the evidence shows

HemoHIM is often described as an immune “modulator”. That idea comes mostly from laboratory and animal research. The human studies are few and small, and some were run by the developer:

• KAERI studies (2006, 38 participants; 2007, 88 participants) reported changes in immune markers such as natural killer (NK) cell activity over about two months. NK cells are part of the body’s first-line immune defence. In the 2007 study, NK-cell activity and some immune signalling molecules increased over two months; in the smaller 2006 study, the increase was significant only in one subgroup.

• A 2022 randomized, placebo-controlled trial (Seo et al.) in 96 adults with fatigue found lower fatigue scores than placebo after 8 weeks.

• A 2025 safety trial (Seo et al.) in 96 healthy adults found no clinically significant adverse events over 8 weeks. The trial was supported by the manufacturer, Kolmar BNH, and included only adults aged 30–59.

Everything else — research on radiation, cancer, the liver, the kidneys, allergies or inflammation — comes from laboratory and animal studies only. These results cannot be taken as effects in people. Changes in immune markers also do not prove fewer infections. Read the details in our overview of HemoHIM clinical studies.

Safety and who should avoid it

In the 8-week safety trial of 96 healthy adults, no clinically significant adverse events were found. An animal study (Toxicological Research, 2025) found no treatment-related toxicity in rats at up to 2,000 mg/kg per day for 13 weeks, and no genotoxicity in standard tests. Long-term human data are limited.

• Children, pregnant women and breastfeeding women should not take it (the Korean label advises against use in these groups).

• If you take blood thinners (anticoagulants) or immunosuppressants, ask your doctor or pharmacist first.

• If you have an autoimmune disease or liver disease, or have surgery planned, talk to your doctor before using it.

• It contains honey and corn syrup — worth knowing if you watch your sugar intake.

See our HemoHIM side effects and safety guide for more.

The 2021 Hong Kong and Taiwan warnings

On 1–2 November 2021, Hong Kong’s Department of Health urged the public not to buy or use HemoHIM after four cases of liver injury in women aged 42 to 72, and after methoxsalen — a prescription drug not declared on the label — was found in samples. Taiwan issued a warning the same month, and the product was withdrawn in Hong Kong, Taiwan and Singapore. Whether HemoHIM itself caused the liver cases is debated; a 2023 review by Yang and colleagues disputes the link. As of October 2026, HemoHIM is sold again in Atomy’s Singapore mall and, as HemoHIM G (艾多美 煥力飲G), in Atomy’s Taiwan mall; it is still not sold in Hong Kong. Our article Is HemoHIM banned? covers what happened and where it stands now.

How to take HemoHIM

The Korean intake is one 20 ml sachet twice a day — for example, one in the morning and one in the evening. You can drink it straight from the sachet. The human studies lasted about eight weeks, so if you try it, judge it honestly after about two months. Do not take more than the label says. More tips are in how to take HemoHIM.

Price and where to buy

Prices vary by country. As an example, in October 2026 a box of 60 sachets (one month at two sachets a day) cost 105 USD in Atomy’s US mall. Registering as an Atomy consumer member was free in the countries we checked.

Buy only from Atomy’s official mall. Resale on marketplaces such as Amazon is not authorized by Atomy, and the origin and storage of that stock cannot be checked. See HemoHIM price and where to buy.

Bottom line

HemoHIM is a Korean herbal supplement with two modest approved claims in South Korea — immune function and fatigue — backed by a few small human trials. Most other claims you will see online come from laboratory or animal research. It appears well tolerated in short trials, but it is not a medicine, it is not FDA approved, and it was the subject of official warnings in Hong Kong and Taiwan in 2021. If you have a health condition or take medicines, ask your doctor before trying it.